Legal17 Apr 2025, 03:11 am
Lupin Loses Initial Round in Myrbetriq® Patent Case with Astellas Pharma in US District Court
AI Summary
Lupin Ltd. has informed the stock exchange about a court order in the matter of a patent case with Astellas Pharma Inc. The United States District Court for the District of Delaware has passed an order in the matter of Myrbetriq® patent case, ruling in favor of Astellas Pharma regarding the validity of its U.S. Patent No. 10,842,780. The court noted that the issues of whether Lupin’s products infringe the 780 patent, damages, and any additional invalidity theories will be litigated at a consolidated jury trial in 2026. Lupin believes it has a strong case and is evaluating further legal action in the matter.
Key Highlights
- Lupin Ltd. loses initial round in Myrbetriq® patent case with Astellas Pharma in US District Court
- United States District Court for the District of Delaware rules in favor of Astellas Pharma regarding the validity of its U.S. Patent No. 10,842,780
- Court noted that the issues of infringement, damages, and additional invalidity theories will be litigated at a consolidated jury trial in 2026
- Lupin believes it has a strong case and is evaluating further legal action in the matter
- No material financial implications as of now